(Q37152761)

18 August 2017

1 reference

title

Current role of gemcitabine in the treatment of Hodgkin lymphoma (English)

1 reference

18 August 2017

Yasuhiro Oki

1

1 reference

18 August 2017

Anas Younes

series ordinal

2

1 reference

18 August 2017

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

49

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

883-889

1 reference

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Autologous bone marrow transplantation for patients with relapsed hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

ESHAP is an active regimen for relapsing Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combina

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801911704

10.1080/10428190801911704

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference